Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT00707512
  4. Details
NCT00707512 Clinical Trial

CD INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Crohn's Disease Clinical Trial

— INFORM  

Official title:
INFORM: Investigating Natalizumab Through Further Observational Research and Monitoring

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00707512
Other study ID # 101CD401
Secondary ID ELN100226-CD451
Status Terminated
Phase
First received
Last updated
Start date June 30, 2008
Est. completion date May 28, 2015

Study information
Verified date May 2024
Source Biogen
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The primary objective of the study is to determine the incidence and pattern of serious and/or clinically significant infections, malignancies, and other serious adverse event (SAE) in participants with Crohn's Disease (CD) treated with natalizumab. The secondary objective of this study in this study population is to evaluate disease severity over time in participants with CD treated with natalizumab based on changes in the Harvey-Bradshaw Index (HBI).

Description:

This study was originally conducted by Elan Pharmaceuticals, Inc. (Elan) in collaboration with Biogen under a protocol written by Elan. Biogen is solely responsible for the study since April 2013.

Recruitment information / eligibility
Status Terminated
Enrollment 87
Est. completion date May 28, 2015
Est. primary completion date May 28, 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Key Inclusion Criteria: - Subjects with Crohn's Disease (CD) who are eligible for therapy according to US Tysabri label and who are enrolled in the Tysabri Outreach Unified Commitment to Health (TOUCH) Prescribing Program. Key Exclusion criteria: - None Note: Other protocol defined Inclusion/ Exclusion criteria may apply.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• natalizumab
Administered as specified in the TOUCH Prescribing Program

Locations
Country Name City State
Puerto Rico Research site San Juan
United States Research site Ann Arbor Michigan
United States Research site Atlanta Georgia
United States Research site Baltimore Maryland
United States Research site Boston Massachusetts
United States Research site Boston Massachusetts
United States Research site Chapel Hill North Carolina
United States Research site Charlotte North Carolina
United States Research site Cincinnati Ohio
United States Research site Cleveland Ohio
United States Research site Columbia Missouri
United States Research site Crestview Hills Kentucky
United States Research site Egg Harbor Township New Jersey
United States Research site Gainesville Florida
United States Research site Grapevine Texas
United States Research site Great Neck New York
United States Research site Hamden Connecticut
United States Research site Hartford Connecticut
United States Research site Houston Texas
United States Research site Lake Success New York
United States Research site Lebanon New Hampshire
United States Research site Lexington Kentucky
United States Research site Louisville Kentucky
United States Research site Miami Florida
United States Research site Nashville Tennessee
United States Research site New York New York
United States Research site Oceanside California
United States Research site Plymouth Minnesota
United States Research site Providence Rhode Island
United States Research site Raleigh North Carolina
United States Research site Rochester New York
United States Research site San Francisco California
United States Research site Scottsdale Arizona
United States Research site Tacoma Washington
United States Research site Troy New York
United States Research site Winter Park Florida

Sponsors (1)
Lead Sponsor Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Puerto Rico, 

Outcome
Type Measure Description Time frame Safety issue
Primary Rate of serious and/or clinically significant infections, malignancies, and other SAEs in participants with Crohn's Disease treated with natalizumab Every 6 months for up to 5 years following the first Tysabri infusion
Secondary Measurement of disease severity over time as assessed by change in HBI Every 6 months for up to 5 years following the first Tysabri infusion
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03815851 - Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Surgery N/A
Not yet recruiting NCT06100289 - A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease Phase 3
Completed NCT02883452 - A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis Phase 1
Recruiting NCT04777656 - Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Pediatric Crohn's Disease Patients. Phase 3
Terminated NCT03017014 - A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions
Recruiting NCT06053424 - Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Healthy Participants and Patients With Crohn's Disease Phase 1
Recruiting NCT05428345 - A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
Completed NCT02508012 - Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases N/A
Not yet recruiting NCT02858557 - The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases N/A
Terminated NCT02882841 - MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Patients N/A
Completed NCT02542917 - Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study
Completed NCT03010787 - A First Time in Human Study in Healthy Volunteers and Patients Phase 1
Terminated NCT02417974 - Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) Phase 2
Active, not recruiting NCT02316678 - Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics N/A
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT02197780 - Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD N/A
Completed NCT02193048 - Prospective Evaluation of a Scoring System in Patients Newly Diagnosed With Crohn's Disease
Completed NCT02265588 - Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD). N/A
Recruiting NCT02395354 - Comparative Prospective Multicenter Randomized Study of Endoscopic Treatment of Stenosis in Crohn´s Disease N/A
Completed NCT01951326 - Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Phase 3